# A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR

> **NCT02681809** · PHASE2 · TERMINATED · sponsor: **ThromboGenics** · enrollment: 48 (actual)

## Conditions studied

- Diabetic Retinopathy
- Posterior Vitreous Detachment
- Disease Progression

## Interventions

- **DRUG:** ocriplasmin 0.0625mg
- **DRUG:** ocriplasmin 0.125mg
- **DRUG:** Sham injection

## Key facts

- **NCT ID:** NCT02681809
- **Lead sponsor:** ThromboGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12
- **Primary completion:** 2019-11-18
- **Final completion:** 2019-11-18
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** Slow recruitment rate
- **Last updated:** 2020-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02681809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02681809, "A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02681809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*